Last reviewed · How we verify

Quinvaxem/Tritanrix — Competitive Intelligence Brief

Quinvaxem/Tritanrix (Quinvaxem/Tritanrix) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pentavalent vaccine. Area: Immunology.

marketed Pentavalent vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Quinvaxem/Tritanrix (Quinvaxem/Tritanrix) — Crucell Holland BV. Quinvaxem/Tritanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Quinvaxem/Tritanrix TARGET Quinvaxem/Tritanrix Crucell Holland BV marketed Pentavalent vaccine
DPT-IPV-Hib-Low（Combined Vaccine） DPT-IPV-Hib-Low（Combined Vaccine） Tanabe Pharma Corporation phase 3 Inactivated pentavalent vaccine
DTaP-IPV//PRP~T combined vaccine DTaP-IPV//PRP~T combined vaccine Sanofi phase 3 Inactivated pentavalent vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pentavalent vaccine class)

  1. Crucell Holland BV · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Quinvaxem/Tritanrix — Competitive Intelligence Brief. https://druglandscape.com/ci/quinvaxem-tritanrix. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: